We use cookies to provide you with a better experience. If you continue to use this site, we'll assume you're happy with this. Alternatively, click here to find out how to manage these cookies

hide cookie message
80,258 News Articles

Gaviscon maker ‘coordinated' updates of GP prescription software, says NHS lawsuit

Reckitt Benckiser denies anti-competition charges in £89m NHS lawsuit

Reckitt Benckiser is facing an £89 million lawsuit from the NHS after allegedly co-ordinating updates of GP prescription software so that the cheap version of its Gaviscon heartburn medicine no longer appeared.

The company has been served with High Court papers, which also state it delayed steps to allow generic versions of Gaviscon to appear on the market. It denies the accusations and has said it will "vigorously defend" itself.

When branded medicines' patents have expired and a generic name has been assigned, GPs can use their prescription software to search for the brand and provide patients with an 'open' prescription that refers to its generic name. Pharmacies can then choose which product to provide.

The NHS lawsuit alleges that Reckitt "co-ordinated the updating of computer-based subscribing systems used by GPs", the Financial Times reported, so that only its more expensive Gaviscon Advance product was visible when doctors attempted to prescribe medicine for heartburn sufferers.

Reckitt declined to comment further.

The lawsuit follows a £10.2 million fine issued last week by the Office of Fair Trading, which said Reckitt Benckiser had abused its dominant position "with the intention of limiting pharmacy choice and hindering competition from suppliers of generic medicines".

The OFT investigation found that Reckitt had withdrawn packs of Gaviscon Original, the cheaper product, from the NHS prescription channel after the product's patent had expired but before the publication of the generic name for it. The intention was for more prescriptions to be issued for Gaviscon Advance, because that product is still patent protected and has no alternative generic equivalent, the OFT stated. Reckitt agreed to settle early and reduced its fine from £12 million.

IDG UK Sites

LG G Watch R video review: The most desirable Android Wear smartwatch

IDG UK Sites

Apple's 2014 highlights: the most significant Apple news of 2014

IDG UK Sites

2015 creative trends: leading designers & artists reveal the biggest influences & changes coming th)......

IDG UK Sites

Ultimate iOS 8 Tips: 35 awesome and advanced tips for using iOS 8 on iPhone and iPad